UnitedHealth Group (UNH) saw a 33% drop in shares in 2025 due to fraud allegations, high medical costs, and weak earnings. The company’s aggressive tactics to boost Medicare payments were called out by a Senate committee. Despite ongoing challenges, analysts are optimistic, with some predicting a recovery for UNH in 2026.

Analysts remain bullish on UNH, with Evercore ISI and RBC Capital giving “Outperform” ratings and price targets of $400 and $408, respectively. Bernstein also sees potential, with an “Outperform” rating and a $444 price target. With fourth-quarter earnings expected to drop, strategic changes are hoped to improve financial performance.

Wall Street analysts predict a 69% drop in UNH’s adjusted EPS for Q4 2025, but expect a recovery in fiscal 2026 with a growth of 8%. Despite short-term challenges, analysts believe UNH can overcome them with strategic changes. Overall, UNH has a “Moderate Buy” rating, with a mean price target of $396.61 and potential upside of 16% to 30%.

Read more at Yahoo Finance: UnitedHealth Just Got a Checkup, and UNH Stock Has Some Big Problems to Treat in 2026. The Bull and Bear Cases Now.